^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Lumakras (sotorasib) (KRAS G12C inhibitor) + DT2216 (Bcl-xL degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BCL-X L PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS G12C-mutated cancers
Published date:
03/09/2022
Excerpt:
We assessed the effect of sotorasib alone or in combination with DT2216 ...on KRASG12C-mutated NSCLC, CRC and pancreatic cancer (PC) cell lines...We observed heterogeneous responses to sotorasib alone, whereas its combination with DT2216 strongly inhibited viability of KRASG12C tumor cell lines that partially responded to sotorasib treatment.
DOI:
10.1186/s13045-022-01241-3
